

HYPERION CCA: A phase 2 randomized trial of chemoimmunotherapy with or without liver-directed radiation therapy for advanced intrahepatic cholangiocarcinoma


Koay EJ¹, Ludmir EB¹, Bacchini M², Valle J², Javle M¹
¹The University of Texas MD Anderson Cancer Center
 and ²Cholangiocarcinoma Foundation

Background:

- Patients with unresectable intrahepatic cholangiocarcinoma (iCCA) often succumb to the disease due to growth of the primary tumor in the liver
- The tumor growth causes organ failure from obstruction of the bile ducts and/or compromise of the major blood vessels in the liver
- Systemic chemoimmunotherapy achieves a median overall survival of about 13 months and represents the new standard of care
- Our prior work [1] suggested that liver-directed radiation therapy could achieve high rates of local control and associated with a median overall survival of 21 months for patients with advanced iCCA.
- Here, we will test the hypothesis that liver-directed radiation therapy will improve overall survival compared to chemoimmunotherapy in a phase 2 randomized trial, HYPERION CCA.

Methods:

- The key eligibility criteria include patients with locally advanced iCCA or metastatic iCCA who have received at least 4 cycles of gemcitabine/cisplatin/durvalumab and have had no evidence of progression of disease
- After enrollment, patients will be randomized 2:1 to (1) receipt of liver-directed radiation therapy followed by continuation of chemoimmunotherapy, or (2) continuation of standard of care chemoimmunotherapy for up to 8 cycles followed by maintenance durvalumab
- The primary endpoint is overall survival. Key secondary endpoints are progression free survival, tumor-related liver failure, and quality of life.
- The accrual goal is 126 patients, giving the study 80% power to detect a hazard ratio of 0.57 with a two-sided 5% significance level



Results:

- The trial activated in August, 2025
- Twelve patients enrolled as of 4/1/2026
- 7 sites in North America are planning to open the study
- 3 international sites are interested in collaborating
- We have made announcements through social media and a webinar
- Working with Cholangiocarcinoma Foundation and Rising Tide Foundation to incorporate the patient voice and engage caregivers

Conclusions:

- This study will help define the role of radiation therapy for iCCA
- The trial is open and enrolling with multiple sites preparing to participate

Acknowledgments

Special thanks to Cholangiocarcinoma Foundation, Rising Tide Foundation, AstraZeneca, and Varian.

References

1. De B, et al. *Liver Cancer*, 2022